210 related articles for article (PubMed ID: 36270754)
21. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Kosten T; Aharonovich E; Nangia N; Zavod A; Akerman SC; Lopez-Bresnahan M; Sullivan MA
Addict Behav; 2020 Dec; 111():106538. PubMed ID: 32777606
[TBL] [Abstract][Full Text] [Related]
22. Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.
Stein MD; VanNoppen D; Herman DS; Anderson BJ; Conti M; Bailey GL
J Subst Abuse Treat; 2022 May; 136():108661. PubMed ID: 34801283
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
[TBL] [Abstract][Full Text] [Related]
24. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
25. 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
Rutrick D; Learned SM; Boyett B; Hassman D; Shinde S; Zhao Y
J Subst Use Addict Treat; 2023 Nov; 154():209155. PubMed ID: 37657559
[TBL] [Abstract][Full Text] [Related]
26. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
[TBL] [Abstract][Full Text] [Related]
27. Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
Baxley C; Borsari B; Reavis JV; Manuel JK; Herbst E; Becker W; Pennington D; Batki SL; Seal K
Addict Behav; 2023 Apr; 139():107589. PubMed ID: 36565531
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.
Farrell M; Shahbazi J; Byrne M; Grebely J; Lintzeris N; Chambers M; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Nicholas T; Weiss R; Rodgers C; Cook J; Degenhardt L;
Int J Drug Policy; 2022 Feb; 100():103492. PubMed ID: 34736130
[TBL] [Abstract][Full Text] [Related]
29. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
[TBL] [Abstract][Full Text] [Related]
30. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
[TBL] [Abstract][Full Text] [Related]
31. Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.
Mariani JJ; Dobbins RL; Heath A; Gray F; Hassman H
Am J Addict; 2024 Jan; 33(1):8-14. PubMed ID: 37936553
[TBL] [Abstract][Full Text] [Related]
32. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study.
Ling W; Nadipelli VR; Solem CT; Ronquest NA; Yeh YC; Learned SM; Mehra V; Heidbreder C
J Subst Abuse Treat; 2020 Mar; 110():1-8. PubMed ID: 31952623
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine treatment for opioid use disorder: recent progress.
Parida S; Carroll KM; Petrakis IL; Sofuoglu M
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):791-803. PubMed ID: 31232604
[No Abstract] [Full Text] [Related]
34. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.
Farrell M; Shahbazi J; Chambers M; Byrne M; Gholami J; Zahra E; Grebely J; Lintzeris N; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Weiss R; Rodgers C; Cook J; Degenhardt L;
Int J Drug Policy; 2024 May; 127():104390. PubMed ID: 38522175
[TBL] [Abstract][Full Text] [Related]
35. Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.
Treloar C; Lancaster K; Gendera S; Rhodes T; Shahbazi J; Byrne M; Degenhardt L; Farrell M
Int J Drug Policy; 2022 Sep; 107():103788. PubMed ID: 35816790
[TBL] [Abstract][Full Text] [Related]
36. Early emergency department experience with 7-day extended-release injectable buprenorphine for opioid use disorder.
D'Onofrio G; Perrone J; Hawk KF; Cowan E; McCormack R; Coupet E; Owens PH; Martel SH; Huntley K; Walsh SL; Lofwall MR; Herring A;
Acad Emerg Med; 2023 Dec; 30(12):1264-1271. PubMed ID: 37501652
[TBL] [Abstract][Full Text] [Related]
37. Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Bastien G; McAnulty C; Ledjiar O; Socias ME; Le Foll B; Lim R; Hassan AN; Brissette S; Marsan S; Talbot A; Jutras-Aswad D;
Can J Psychiatry; 2023 Aug; 68(8):572-585. PubMed ID: 36519188
[TBL] [Abstract][Full Text] [Related]
38. Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.
Montgomery L; Winhusen T; Scodes J; Pavlicova M; Twitty D; Campbell ANC; Wang AL; Nunes EV; Rotrosen J
J Subst Abuse Treat; 2021 Nov; 130():108489. PubMed ID: 34118716
[TBL] [Abstract][Full Text] [Related]
39. Extended-release buprenorphine outcomes among treatment resistant veterans.
Cotton AJ; Lo K; Kurtz FB; Waldbauer L
Am J Drug Alcohol Abuse; 2022 May; 48(3):334-337. PubMed ID: 34780319
[No Abstract] [Full Text] [Related]
40. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Mannelli P; Douaihy AB; Akerman SC; Legedza A; Fratantonio J; Zavod A; Sullivan MA
Am J Addict; 2022 Mar; 31(2):142-147. PubMed ID: 35137481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
